Experts’ Advice for the week of 26 Feb to 2 Mar, 2018

Experts’ Advice for the week of 26 Feb to 2 Mar, 2018

Expert Advice 26-02-18 to 02-03-18
 

1. Yes Bank

Research House: BoA ML

Advice: BUY
CMP Rs.: 316
1 Year Target Rs.: 475
Potential Upside: 50%
Experts’ Comments:

Maintain BUY.
Yes Bank is the key beneficiary of the uptick in loan growth. It also has minimal exposure to accounts likely to be referred under the Indian Bankruptcy Code.

2. Marksans Pharma

Research House: Centrum Research

Advice: BUY
CMP Rs.: 38
1 Year Target Rs.: 55
Potential Upside: 44%
Experts’ Comments:

Upgrade to BUY.
Marksans Pharma’s performance will improve, led by the recent launch of four new products in the US and expected approvals for softgel capsules from the USFDA.

3. Jet Airways

Research House: India Nivesh

Advice: BUY
CMP Rs.: 735
1 Year Target Rs.: 1010
Potential Upside: 38%
Experts’ Comments:

Initiate BUY.
The company is focusing on improving profitability by reducing expenses-upgrading its fleet, designs changes to existing aircraft and renegotiating existing contracts.

4. Indo Count Ind.

Research House: Kotak Securities

Advice: BUY
CMP Rs.: 101
1 Year Target Rs.: 135
Potential Upside: 34%
Experts’ Comments:

Upgrade to BUY.
There has been a price correction. Though destocking continued to impact volume offtake in the US market, the intensity of destocking has reduced.

5. SBI Life

Research House: HDFC Securities

Advice: BUY
CMP Rs.: 666
1 Year Target Rs.: 840
Potential Upside: 16%
Experts’ Comments:

Initiate BUY.
SBI Life is a play on the under penetrated Indian insurance market. Its new business premium is expected to show a CAGR of 18.9% between 2016-17 and 2019-20.

6. Infosys

Research House: Ambit Capital

Advice: BUY
CMP Rs.: 1161
1 Year Target Rs.: 1350
Potential Upside: 16%
Experts’ Comments:

Maintain BUY.
Continue to prefer the company because of its strong portfolio, contemporary sales strategy, focus on reskilling initiatives and high quality management team.

7. Lupin

Research House: IIFL

Advice: Reduce (Sell)
CMP Rs.: 801
1 Year Target Rs.: 700
Potential Upside: 13%
Experts’ Comments:

Retain REDUCE.
EBITDA margins will continue to be under pressure due to the likely erosion in the Metformin franchise and high single digits price erosion is expected in its US business.


Watch this blog video here : https://youtu.be/KCPuvgDiOwI

WATCH THIS BLOG’S FULL VIDEO HERE : https://youtu.be/LQJ33SFxkxs
 
Our Blog website : http://multibaggerspoint.com/

Follow us on Facebook : https://www.facebook.com/multibaggerspoint1

Follow us on YouTube : https://www.youtube.com/multibaggerspoint


Disclaimer:

My descriptions, videos, presentations are only for educational and information purposes and under no circumstances should be used for making investment decisions. I cannot guarantee the accuracy of any information provided.
The stocks picks are based on my own research and personal views and sometimes are from newspapers, tv channel program, magazines, etc. No part of compensation is or will be directly or indirectly related to the views and recommendations of this research. I have not served as an officer director or employee of company and have not been engaged in market – making activity of the company covered in the research report.
Consult qualified financial advisor before making any investment decision.

 

Leave a Reply

Your email address will not be published. Required fields are marked *